Life Science Compliance Update

April 18, 2018

It’s Not All About the Money - Medtronic’s Infusion Multi-State Settlement Agreement


In a closely watched matter culminating years of litigation, Medtronic on December 12, 2017, entered into a $12 Million multi-state settlement resolving allegations that the medical device company had misled consumers about the safety, efficacy, and effectiveness of its Infuse® Bone Graft Device (“Infuse”). The settlement represents continued coordination among States to prosecute marketing fraud and false advertising within the medical device industry.

Within both the U.S. medical device manufacturing arena as well as the life science compliance communities, few companies stand out like Medtronic Sofamor Danek, U.S.A, Inc. (“Medtronic”). Medtronic has long been considered a leader in ethics and compliance for medical devices. In fact, in 2017, AdvaMed awarded its coveted MedTech Ethical Leadership Award, which is sponsored by PwC, to Thomas Schumacher, Medtronic’s Chief Compliance Officer, for demonstrating “outstanding leadership in the advancement of ethics and ethical behavior in the medical device and diagnostics industry.”

However, Medtronic, a leading manufacturer of devices for use in spinal surgery, also has had its share of missteps with government authorities. In December 2017, Medtronic settled its most recent issue with multiple state attorneys general. This case is notable not for the size of the settlement ($12 million), but rather for the remedial actions Medtronic agreed to, as well as the proposition that even good companies, with robust compliance programs, can still have problems.

To Read the Full Story, Subscribe, Download a Sample Issue, or Sign In

April 17, 2018

Nicodemo (Nico) Fiorentino Joins Life Science Compliance Update as Associate Editor


As Life Science Compliance Update enters its fourth year of publication, it is a great pleasure to announce that Nicodemo Fiorentino joins Thomas Sullivan, Publisher and Dr. Seth Whitelaw, Editor as a member of the Update’s editorial staff. 

“Nico brings an outstanding mix of passion, scholarship and pure writing ability that will only enhance quality of the publication,” said Sullivan.  “It is aligned with our goal to create a single resource that allows busy compliance professionals and business executives to read less but become more attuned.”

“It’s a sign that both the topics we cover and the Update itself are growing,” said Whitelaw. “We have so much going on every month that it is a challenge to get the critical information and insights out quickly enough.  Nico, will help us continue to bridge the knowledge gaps between the most experienced practitioners and those with less time in the profession.”

In addition to being a member of the Editorial Board and a frequent contributor on multiple topics, including drug pricing transparency, to the Update, Nicodemo Fiorentino, currently is a member of G&M Health LLC., which provides a wide range of services to the life science industry. A New Jersey native, he received his bachelor’s degree, with honors, in History from Rowan University, Glassboro, New Jersey and his Juris Doctor (J.D.) from Rutgers University School of Law, Camden, New Jersey.

April 16, 2018

Data Analytics & Detecting Medicare Fraud – A Promising Idea Still Awaiting Proof of Concept


For analyzing so-called “Big Data” sets, data analytics is an invaluable set of tools and techniques. Now the HHS OIG plans to expand its efforts to use data analytics to detect Medicare fraud. While promising, it remains to be proven that the tool and techniques will be cost-effective in this context.

The fiscal year 2017 was a big year for the Office of Inspector General of the Department of Health and Human Services (“OIG”). Among many important accomplishments, the OIG undertook “the largest healthcare fraud takedown in history,” involving more than 400 defendants and more than $1.3 billion in false billings to Medicare and Medicaid.

This action was notable not just for the number of defendants involved and the amount of money recovered, but for the fact that as characterized by the OIG, it was a “data-driven effort.” Therefore, the case represents a signature moment in the evolution of healthcare fraud enforcement, as we transition from a “pay and catch” approach to using data analytics to support targeted enforcement.

To Read the Full Story, Subscribe, Download a Sample Issue, or Sign In


Preview | Powered by FeedBlitz


April 2018
Sun Mon Tue Wed Thu Fri Sat
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30